Taiwan
· Delayed Price · Currency is TWD 3D Global Biotech Statistics
Total Valuation
3D Global Biotech has a market cap or net worth of TWD 3.74 billion. The enterprise value is 3.41 billion.
| Market Cap | 3.74B |
| Enterprise Value | 3.41B |
Important Dates
The next estimated earnings date is Monday, March 24, 2025.
| Earnings Date | Mar 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
3D Global Biotech has 76.81 million shares outstanding. The number of shares has increased by 7.54% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 76.81M |
| Shares Change (YoY) | +7.54% |
| Shares Change (QoQ) | +12.70% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 3.25% |
| Float | 67.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 53.02 |
| PB Ratio | 7.13 |
| P/TBV Ratio | 10.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -115.96 |
| EV / Sales | 61.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -249.70 |
Financial Position
The company has a current ratio of 6.79, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.79 |
| Quick Ratio | 5.98 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.52 |
| Interest Coverage | -267.38 |
Financial Efficiency
Return on equity (ROE) is -7.64% and return on invested capital (ROIC) is -5.54%.
| Return on Equity (ROE) | -7.64% |
| Return on Assets (ROA) | -5.11% |
| Return on Capital (ROIC) | -5.54% |
| Revenue Per Employee | 1.67M |
| Profits Per Employee | -891,152 |
| Employee Count | 33 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 0.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +150.26% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +150.26% |
| 50-Day Moving Average | 40.37 |
| 200-Day Moving Average | 36.97 |
| Relative Strength Index (RSI) | 74.75 |
| Average Volume (20 Days) | 912,945 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 3D Global Biotech had revenue of TWD 55.15 million and -29.41 million in losses. Loss per share was -0.49.
| Revenue | 55.15M |
| Gross Profit | 35.36M |
| Operating Income | -35.03M |
| Pretax Income | -30.38M |
| Net Income | -29.41M |
| EBITDA | -18.79M |
| EBIT | -35.03M |
| Loss Per Share | -0.49 |
Balance Sheet
The company has 341.43 million in cash and 7.12 million in debt, giving a net cash position of 334.31 million or 4.35 per share.
| Cash & Cash Equivalents | 341.43M |
| Total Debt | 7.12M |
| Net Cash | 334.31M |
| Net Cash Per Share | 4.35 |
| Equity (Book Value) | 457.04M |
| Book Value Per Share | 6.84 |
| Working Capital | 333.29M |
Cash Flow
In the last 12 months, operating cash flow was -11.05 million and capital expenditures -2.61 million, giving a free cash flow of -13.66 million.
| Operating Cash Flow | -11.05M |
| Capital Expenditures | -2.61M |
| Free Cash Flow | -13.66M |
| FCF Per Share | -0.18 |
Margins
Gross margin is 64.12%, with operating and profit margins of -63.51% and -53.32%.
| Gross Margin | 64.12% |
| Operating Margin | -63.51% |
| Pretax Margin | -55.09% |
| Profit Margin | -53.32% |
| EBITDA Margin | -34.07% |
| EBIT Margin | -63.51% |
| FCF Margin | n/a |
Dividends & Yields
3D Global Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.54% |
| Shareholder Yield | -7.54% |
| Earnings Yield | -1.01% |
| FCF Yield | -0.36% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
3D Global Biotech has an Altman Z-Score of 15.73.
| Altman Z-Score | 15.73 |
| Piotroski F-Score | n/a |